12.01
-0.36 (-2.91%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Ginkgo Bioworks Holdings, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 价值 35% | -0.7 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -0.7 |
| 时机 35% | 0.3 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 0.5 |
| 技术平均移动指标 参考 | 0.0 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×1.21 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -22.4% |
| 支柱一致性 | ×0.95 |
| 不计入评分 | |
| 价格波动 参考 | -5.0 |
| 最终评分 | -0.16 |
|
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 6.88% |
| 机构持股比例 | 77.96% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Erste Asset Management Gmbh | 30 Jun 2026 | 2,536,939 |
| Anchorage Capital Group, L.L.C. | 30 Jun 2026 | 1,746,363 |
| Forbes J M & Co Llp | 30 Sep 2026 | 977,371 |
该时间范围内无数据。
该时间范围内无数据。
投资组合